These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 17044086

  • 1. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
    Kosaka T, Miyajima A, Takayama E, Kikuchi E, Nakashima J, Ohigashi T, Asano T, Sakamoto M, Okita H, Murai M, Hayakawa M.
    Prostate; 2007 Jan 01; 67(1):41-9. PubMed ID: 17044086
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer.
    Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M.
    Clin Cancer Res; 2006 May 01; 12(9):2888-93. PubMed ID: 16675585
    [Abstract] [Full Text] [Related]

  • 3. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
    Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S, Kikkawa F.
    Clin Cancer Res; 2005 Apr 01; 11(7):2686-94. PubMed ID: 15814650
    [Abstract] [Full Text] [Related]

  • 4. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer.
    Kosaka T, Miyajima A, Shirotake S, Kikuchi E, Hasegawa M, Mikami S, Oya M.
    Prostate; 2010 Feb 01; 70(2):162-9. PubMed ID: 19760626
    [Abstract] [Full Text] [Related]

  • 5. Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway.
    Fan F, Tian C, Tao L, Wu H, Liu Z, Shen C, Jiang G, Lu Y.
    Biomed Pharmacother; 2016 Oct 01; 83():704-711. PubMed ID: 27470571
    [Abstract] [Full Text] [Related]

  • 6. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer.
    Kosugi M, Miyajima A, Kikuchi E, Kosaka T, Horiguchi Y, Murai M.
    Hum Cell; 2007 Feb 01; 20(1):1-9. PubMed ID: 17506771
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer.
    Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang Y, Sun L, Sui G, Cai L, Dong X.
    Cancer Lett; 2013 Jan 28; 328(2):318-24. PubMed ID: 23092556
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y, Ma Y, Lu HP, Gao JH, Liang CS, Liu CZ, Zou JT, Wang HQ.
    Chin Med J (Engl); 2008 Nov 20; 121(22):2284-9. PubMed ID: 19080333
    [Abstract] [Full Text] [Related]

  • 9. Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate cancer.
    Kosaka T, Miyajima A, Shirotake S, Kikuchi E, Oya M.
    Prostate; 2011 Oct 01; 71(14):1510-7. PubMed ID: 21321983
    [Abstract] [Full Text] [Related]

  • 10. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T, Nakamura K, Araki H, Kusaka M, Yamaoka M.
    Cancer Res; 2003 Sep 01; 63(17):5622-8. PubMed ID: 14500404
    [Abstract] [Full Text] [Related]

  • 11. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis.
    Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T, Hayakawa M.
    Cancer Res; 2002 Aug 01; 62(15):4176-9. PubMed ID: 12154013
    [Abstract] [Full Text] [Related]

  • 13. A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy.
    Bao X, Wang W, Wang C, Wang Y, Zhou J, Ding Y, Wang X, Jin Y.
    Biomaterials; 2014 Sep 01; 35(29):8450-66. PubMed ID: 24997481
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer.
    Kosugi M, Miyajima A, Kikuchi E, Kosaka T, Horiguchi Y, Murai M, Oya M.
    Urology; 2009 Mar 01; 73(3):655-60. PubMed ID: 19167032
    [Abstract] [Full Text] [Related]

  • 15. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
    Iwasa Y, Mizokami A, Miwa S, Koshida K, Namiki M.
    Int J Urol; 2007 Mar 01; 14(3):233-9. PubMed ID: 17430262
    [Abstract] [Full Text] [Related]

  • 16. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells.
    Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K.
    Clin Cancer Res; 2006 May 15; 12(10):3003-9. PubMed ID: 16707595
    [Abstract] [Full Text] [Related]

  • 17. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
    Cheng L, Zhang S, Sweeney CJ, Kao C, Gardner TA, Eble JN.
    Anticancer Res; 2004 May 15; 24(4):2135-40. PubMed ID: 15330153
    [Abstract] [Full Text] [Related]

  • 18. Candesartan, an angiotensin II type 1 receptor antagonist, inhibits pathological retinal neovascularization by downregulating VEGF receptor-2 expression.
    Nakamura S, Tsuruma K, Shimazawa M, Hara H.
    Eur J Pharmacol; 2012 Jun 15; 685(1-3):8-14. PubMed ID: 22543084
    [Abstract] [Full Text] [Related]

  • 19. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
    Yazici S, Kim SJ, Busby JE, He J, Thaker P, Yokoi K, Fan D, Fidler IJ.
    Prostate; 2005 Nov 01; 65(3):203-15. PubMed ID: 15948138
    [Abstract] [Full Text] [Related]

  • 20. Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis.
    Alhusban A, Al-Azayzih A, Goc A, Gao F, Fagan SC, Somanath PR.
    J Pharmacol Exp Ther; 2014 Sep 01; 350(3):635-45. PubMed ID: 24990940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.